97 results
424B4
PCSA
Processa Pharmaceuticals Inc
29 Jan 24
Prospectus supplement with pricing info
4:15pm
to delay, reduce or eliminate some or all of our research and development programs, or we may be unable to continue operations. Although we continue … of proceeds from this offering. We currently intend to use the net proceeds from this offering for continued research and development for NCG-Cap
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
25 Jan 24
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
8:35am
., President of Research and Development at Processa. “This greater exposure suggests that NGC-Cap can distribute more 5-FU to the cancer cells, potentially
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
19 Jan 24
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
8:00am
, PharmD, Ph.D., President of Research and Development at Processa. “Capecitabine is already approved as both monotherapy and combination therapy
8-K
EX-99.1
5fvt i94hbjq
19 Dec 23
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
9:00am
8-K
622dmmqi0jzdzewg
16 Nov 23
Regulation FD Disclosure
3:10pm
8-K
j8usv8 mx
17 Aug 23
Regulation FD Disclosure
12:00pm
8-K
ghisrn78fq4odjopx8m
8 Aug 23
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
10:30am
8-K
EX-99.1
g07fwzhxqv 7ebfmvo
8 Aug 23
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
10:30am
8-K
EX-99.1
nzj74luftf31mij0
31 Mar 23
Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
8:30am